Seeking Alpha

Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases

Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup ...
Drexel University

Minor in Immune Engineering

The purpose of this undergraduate minor is to leverage Drexel’s unique strengths and leadership in this area to advance the education of the next generation of leaders in immune engineering. Students ...
MarketWatch

DifGen Pharmaceuticals and Aveva Drug Delivery Systems Lead U.S. Technology Transfer and Platform Development Collaboration for Multi-Indication Immune Restoration Therapy with ...

The MarketWatch News Department was not involved in the creation of this content. MIRAMAR, Fla., March 25, 2026 /PRNewswire/ -- DifGen Pharmaceuticals and Aveva Drug Delivery Systems today announced a ...
Seeking Alpha

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

The Michael J. Fox Foundation grant supports the development of AC Immune’s first-in-class TDP-43 PET tracer program Target ALS Foundation grant supports collaboration between AC Immune and ...
Nasdaq

Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune System

Milestone marks the third major acquisition for an IFM Therapeutics subsidiary in the past seven years The acquisition provides Novartis with full rights to IFM Due's portfolio of STING antagonists, ...